Tabula Rasa HealthCare (TRHC) Posts Wider Q1 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- Wall St indexes climb as US, Iran halt attacks; Comcast surges on spin-off plan
- Tech funds suffer record outflows as investors trim equity positions
- Comcast shares surge 23% on blockbuster plan to spin off NBCUniversal and Sky
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- Needham Starts NeoVolta (NEOV) at Buy
- Personalis, Inc. (PSNL) and Tempus (TEM) Expand Collaboration
- Strategy stock jumps 7% as firm shifts to active capital management
- TD Cowen: 'Sober View Suggests Structural Alcohol Risks Are Overblown'
Tabula Rasa HealthCare Reports First Quarter 2022 Results
May 5, 2022 4:03 PM EDTFirst quarter 2022 revenue of $67.1 million from continuing operations includes CareVention HealthCare revenue of $66.3 million, up 19% vs. a year agoPlanned sales of PrescribeWellness, SinfonÃaRx, and DoseMe expected to add significant liquidity, reduce net debt, and provide financial flexibilityGAAP net loss from continuing operations of $20.4 millionAdjusted EBITDA of $2.5 million
MOORESTOWN, N.J., May 5, 2022 /PRNewswire/ -- Tabula Rasa HealthCare, Inc. ("TRHC", the "Company," "we," "us," or "our") (Nasdaq: TRHC), a leading healthcare technology company advancing the safe use of medications, today reported financial results for the first... More
